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Lung cancer is the leading cause of cancer death in North America
(Parker et al, 1996). The majority of cases are of non-small cell
histology, and most present with locally advanced or metastatic
disease. Although modest survival gains have been made with
cisplatin-based combination chemotherapy (Non-small Cell Lung
Cancer Collaborative Group, 1995), the treatment for patients with
advanced non-small cell lung cancer (NSCLC) has been unsatis-
factory (Steward and Dunlop, 1995). However, several new agents
with encouraging response rates (Goss et al, 1996) and modest
toxicity (Thatcher et al, 1995) are giving oncologists cause for
optimism about improving treatment results.
The taxanes have shown impressive activity in a number of
human cancers, including NSCLC (Rowinsky and Donehower,
1995). Both paclitaxel (Taxol®) and its semisynthetic analogue
docetaxel have shown response rates above 20% in uncontrolled
trials (Fossella et al, 1994; Francis et al, 1994). Paclitaxel is
particularly interesting because of reported survival rates at 1 year
of 40% (Chang et al, 1993; Murphy et al, 1993).
We have previously reported that single-agent paclitaxel may be
a cost-effective therapy for stage IV NSCLC when compared with
best supportive care (BSC) on the basis of phase II analyses (Earle
and Evans, 1997). Recently, a three-arm phase III study by the
Eastern Cooperative Oncology Group (ECOG) has compared
standard cisplatin plus etoposide versus cisplatin plus paclitaxel
at two different dose levels, with or without granulocyte colony-
stimulating factor (G-CSF) (Bonomi et al, 1996, 1997). It found
higher response rates and a statistically significant improve-
ment in survival in the paclitaxel-containing arms compared to
etoposide/cisplatin. There was also a trend towards improved
1-year survival.
However, in a time of increasing fiscal constraint, the cost of
new interventions is a concern that can inhibit their adoption
into routine practice. Knowledge of their effectiveness relative to
cost can better inform resource allocation decisions. Therefore,
we undertook this study to estimate the cost-effectiveness of
paclitaxel plus cisplatin in advanced NSCLC management,
relative to standard etoposide plus cisplatin.
METHODS
The ECOG 5592 trial
Our analysis is based on this three-arm randomized comparison of
599 patients with stage IIIb or IV NSCLC. The groups were
treated with:
Cost-effectiveness of paclitaxel plus cisplatin in
advanced non-small-cell lung cancer
CC Earle and WK Evans
Ottawa Regional Cancer Centre, University of Ottawa and Cancer Care Ontario, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
Summary The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with
standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource
utilization data from a large three-arm randomized trial comparing: paclitaxel 135 mg m–2 by 24-h intravenous (i.v.) infusion + cisplatin;
paclitaxel 250 mg m–2 by 24-h i.v. infusion + cisplatin + granulocyte colony-stimulating factor (G-CSF); and standard etoposide/cisplatin in
patients with stage IIIb or IV NSCLC. We also modelled the regimens with paclitaxel 135 mg m–2 + cisplatin administered as an outpatient by
3-h infusion, as clinical data suggest that this is equivalent to 24-h infusion. We collected costing data from the Ottawa Regional Cancer
Centre and applied it to the resources consumed in the randomized trial. We integrated these data into the Statistics Canada POpulation
HEalth Model (POHEM), which generated hypothetical cohorts of patients treated with each regimen. The POHEM model assigned diagnostic
work-up, treatment, disease progression and survival characteristics to each individual in these cohorts and tabulated the costs associated
with each. We did sensitivity analyses around the costs of chemotherapy and its administration, and the survival differences between the two
regimens. All costs are in 1997 Canadian dollars ($1.00 Canadian ~ £0.39 sterling). The perspective is that of the Canadian health care
system. In the trial, the two paclitaxel-containing arms had almost identical survival curves with a median survival of 9.7 months compared
with 7.4 months for etoposide/cisplatin. As administered in the trial, paclitaxel/cisplatin cost $76 370 per life-year gained (LYG) and
paclitaxel/cisplatin/G-CSF $138 578 per LYG relative to etoposide/cisplatin. However, when modelled as an outpatient 3-h infusion,
paclitaxel/cisplatin was moderately cost-effective at $30 619 per LYG. When compared with historical controls treated with best supportive
care, this regimen of paclitaxel/cisplatin cost $4539 per LYG. Assuming a 3-h paclitaxel infusion yields the same survival advantage as the 24-
h infusion did in the randomized trial, paclitaxel/cisplatin is a cost-effective improvement over standard etoposide/cisplatin for patients with
advanced non-small cell lung cancer.
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The response rates were found to be higher with the paclitaxel-
containing regimens: 26% in the paclitaxel/cisplatin group and
31% in the paclitaxel/cisplatin/G-CSF group, versus 12% for the
etoposide/cisplatin group. The two paclitaxel-containing arms
had almost identical survival and were grouped together for
survival analysis. This revealed a statistically significant improve-
ment in the median survival, 9.7 months in the combined
paclitaxel arms compared with 7.4 months for etoposide/cisplatin
(log-rank P = 0.049). Additionally, 39% of patients treated with
paclitaxel/cisplatin and 40% of those treated with paclitaxel/
cisplatin/G-CSF were alive at 1 year, compared to 32% of those
receiving etoposide/cisplatin. However, this was not statistically
significant.
Five of seven quality of life indices assessed during the trial did
not differ among the three treatment arms. The remaining two
domains favoured those treated with paclitaxel-containing
regimens: lung cancer symptoms were significantly better in the
paclitaxel-treated patients (P = 0.027) and there was a trend
towards improved emotional well-being (P = 0.079).
Determination of treatment costs
In order to assess treatment costs, we obtained resource utilization
data from the ECOG randomized trial. To ascertain the total direct
cost to the Canadian health care system for these treatments, we
had to make a number of assumptions. We determined the average
doses and number of treatment cycles from the pooled drug
administration records of patients in the trial and assumed that
each patient in our analysis received this same treatment. We
assumed that the 24-h infusions required 1 day of hospitalization.
However, we also modelled the effect of giving paclitaxel
135 mg m–2 by a 3-h outpatient infusion as is the current practice at
the Ottawa Regional Cancer Centre (ORCC). We assumed there
was no drug wastage.
Hospitalization for complications occurred in 8.8% of etopo-
side/cisplatin cycles, compared to 7.4% for paclitaxel/cisplatin and
9.0% for paclitaxel/cisplatin/G-CSF. These hospitalizations were
predominantly for haematologic toxicity. We calculated the
average cost for such admissions through the Ottawa General
Hospital Case Costing System. We obtained physician fees from
the most recent Ontario Health Insurance Plan (OHIP) Schedule of
Benefits. Because the investigations done in a clinical trial often
do not reflect usual practice, we modelled the pretreatment blood
work and imaging tests required prior to and during chemotherapy
administration on those used in routine care at the ORCC. We
determined the cost of these tests from the OHIP Schedule of
Benefits. We assumed that test results were not duplicated as
patients moved through the health care system.
The amount of time spent by nursing and pharmacy personnel
involved in preparing and administering each type of
chemotherapy was measured by the staff of the ORCC. We
calculated the cost of personnel time by multiplying the amount of
professional time expended by the 1997 hourly rates at the ORCC.
Finally, nursing staff tracked and costed the actual supplies used in
the preparation of paclitaxel. We extracted the ‘hotel’ costs of
clinic visits from the BR 5 study and inflated them to 1997 dollars.
We assumed the cost of terminal care hospitalization for patients
receiving paclitaxel to be similar to that of patients receiving
chemotherapy in the BR 5 study, as determined in the economic
analysis of that trial (Jaakkimainen et al, 1990).
Survival data
We obtained the raw survival data of patients in the ECOG
randomized trial (Bonomi et al, 1996, 1997) from Bristol-Myers
Squibb. We incorporated it into our model using a piecewise
Weibull function (Figure 1) and determined the average survival
gain. The Weibull function is a standard, flexible, parametric
survival model commonly used by biostatisticians to model failure
time data in cancer patients.
The lung cancer costing model
Statistics Canada developed the lung cancer costing model as part
of a larger project to simulate the health of Canadians. The
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Figure 1 Survival curves for the combined paclitaxel/cisplatin arms compared to etoposide/cisplatin in stage IIIb and IV non-small-cell lung cancerPOpulation HEalth Model (POHEM) is a software framework that
integrates data on risk factors for major diseases, disease onset and
outcome, health care utilization and direct care costs. The model
generates a hypothetical cohort of people with demographic and
labour force characteristics, risk factor exposures and health histo-
ries typical of Canadians. The perspective of the costing model is
that of a provincial government payer in a universal health care
system.
We have reported the lung cancer costing submodel previously
(Evans et al, 1993, 1995a, 1995b, 1995c, 1997a, 1997b; Evans and
Chevalier, 1996; Earle and Evans, 1997). In brief, it assigns indi-
viduals to a particular histologic cell type based on the distribution
of these characteristics in the Canadian Cancer Registry. Stage
distribution is based on retrospective chart reviews. It then assigns
diagnostic work-up, treatment, disease progression and survival
characteristics based on data from the medical literature, provin-
cial registries and nationwide physician surveys. Finally, it allo-
cates costs to the various components of care appropriate for cell
type and stage of disease, from initial diagnosis through to
terminal care. We assumed that terminal care costs were similar for
patients in the three study arms. The model has recently been
updated with 1992 incidence data. All costs are in 1997 Canadian
dollars ($1.00 Canadian ~ £0.39 sterling). Because survival is very
short for these patients, discounting was not applied.
We integrated the cost and survival data described above into
POHEM to carry out our analyses. Cost-effectiveness, expressed
as the cost per life-year gained (LYG) was calculated by the
formula:
Sensitivity analyses
Because clinical trials often produce efficacy results that are
superior to those seen in routine practice, we did sensitivity
analyses in which we decreased the survival differences between
the regimens by 25 and 50%. A generic version of paclitaxel has
recently become available in Canada, resulting in a decrease in
price. Therefore, we did sensitivity analyses around the cost of
chemotherapy and its administration, increasing it to pre-generic
pricing. Because the majority of stage IV lung cancer patients in
Canada are still managed without palliative chemotherapy (Raby
et al, 1995), we also compared the survival of paclitaxel/cisplatin-
treated patients to that of best supportive care (BSC). To do this,
we modelled the survival of patients managed by BSC on the
NCIC BR 5 trial (Jaakkimainen et al, 1990), a three-armed
randomized trial comparing BSC to two chemotherapy regimens
(Figure 2). We also did analyses restricted to stage IV patients
only, as they did not benefit as much from chemotherapy as stage
III patients in the ECOG 5592 trial.
RESULTS
Principal analysis
Table 1 presents a summary of the direct costs of chemotherapy
administration for the different arms assessed in our model. In the
ECOG 5592 study, patients in the etoposide/cisplatin arm received
a median of four cycles of chemotherapy, as did those in the pacli-
taxel/cisplatin/G-CSF arm, while those in the paclitaxel/cisplatin
arm received a median of five treatment cycles. The total cost of
administering a course of paclitaxel (135 mg m–2)cisplatin was
$13 841 when given by 24-h infusion as an inpatient. This fell to
$7832 when we modelled it at the same doses as an outpatient
3-h infusion. Paclitaxel, G-CSF and inpatient hospital care were
the largest contributors to the cost of treatment.
The average survival of patients treated with paclitaxel/cisplatin
calculated from the combined arms of the ECOG study exceeds
that of etoposide/cisplatin by 1.6 months. From these data we were
able to calculate that the paclitaxel/cisplatin arm as given in the
trial costs $76 370 per LYG, while the paclitaxel/cisplatin/G-
CSF regimen costs $138 578 per LYG. However, if the
paclitaxel/cisplatin regimen could be given as an outpatient with
the same effectiveness, the cost-effectiveness would improve to
$30 619 per LYG (Table 2).
To put these numbers into a national perspective, in 1992 there
were 4986 cases of stage IV NSCLC in Canada. The total cost to
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Figure 2 Survival curves for the combined paclitaxel/cisplatin arms of the ECOG 5592 study compared to best supportive care arm of the NCIC BR-5 study in
stage IV non-small-cell lung cancertreat all of these with best supportive care would be $140 965 903.
Treating them all with outpatient paclitaxel/cisplatin would cost
$155 332 287, a difference of $15 366 384 (10%).
Sensitivity analysis
Table 3 shows the effects of varying selected assumptions in the
model. If the survival gain was only 50% of that reported, the cost-
effectiveness ratio would rise to $71 321 per LYG. Considering
only stage IV patients, who had less survival gain in the trial, the
cost-effectiveness was still acceptable at $44 756. Using the
higher cost of paclitaxel before it became generic, the cost-effec-
tiveness ratio rose to $49 028. In non-randomized comparisons
with BSC, paclitaxel/cisplatin cost $4539 per LYG for stage IIIb
and IV patients, and $5114 per LYG if the analysis was restricted
to stage IV patients.
DISCUSSION
Our study suggests that the paclitaxel/cisplatin regimen can be a
cost-effective improvement in the treatment of advanced lung
cancer when given on an outpatient basis. Accepted thresholds for
a cost-effective treatment intervention range from $20 000 to
$100 000 per quality adjusted life-year (Laupacis et al., 1992).
Most of our cost estimates fall within these guidelines.
High-dose paclitaxel given by 24-h inpatient infusion and
supported with G-CSF was clearly not cost-effective when
compared with etoposide/cisplatin. As has been observed in other
situations (Canadian Coordinating Office for Health Technology
Assessment, 1997), this strategy provided no advantage over
lower dose treatment, but resulted in more toxicity. However, we
found paclitaxel/cisplatin to be cost-effective when we modelled it
given as a 3-h outpatient infusion. This assumes that the survival
benefit would be similar despite this modification in its adminis-
tration. Shorter paclitaxel infusions have been reported to be less
toxic than longer infusions, with comparable response rates
(Hainsworth et al, 1995). However, a recent randomized trial
of 3- versus 24-h paclitaxel infusions in breast cancer found the
longer infusion yielded a superior response rate (Mamounas et al,
1998). With respect to survival, two other randomized trials
involving paclitaxel/cisplatin in advanced NSCLC found superior
response rates but were unable to demonstrate a survival advan-
tage for this regimen (Gatzemeier et al, 1998; Giaccone et al,
1998). Neither had standard control arms, so survival may have
been similar in each trial because both regimens were superior to
standard. However, both of these trials gave paclitaxel by 3-h
infusion, raising the possibility that the shorter infusion duration
decreased the survival benefit of treatment.
Our sensitivity analysis showed these results to be robust to
most assumptions. When compared to best supportive care, the
care most often given to advanced lung cancer patients in Canada
(Raby et al, 1995), paclitaxel/cisplatin is a very cost-effective
regimen. However, this analysis relied on a non-randomized
comparison of survival experiences that may not accurately
represent the survival benefit.
We did not directly incorporate quality of life adjustments into
our analysis. In the clinical trial there was no significant difference
in toxicity in any of the three arms. Furthermore, quality of life
measures indicated that quality of life was as good or better in the
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Table 1 Summary of estimated treatment costs for the chemotherapy regimens in ECOG 5592 and ambulatory paclitaxel/cisplatin
Item Etoposide/cisplatin Paclitaxel/cisplatin Paclitaxel/cisplatin/G-CSF Outpatient paclitaxel/cisplatin
Initial diagnosis and staging $11 245 $11 245 $11 245 $11 245
Treatment costs
Number of cycles 4 5 4 5
Laboratory investigations $366 (10%) $458 (3%) $573 (3%) $458 (6%)
Drug costs $1078 (30%) $5755 (42%) $15 017 (68%) $5755 (73%)
Administration $1241 (35%) $6891 (50%) $5512 (25%) $882 (11%)
Toxicity $876 (25%) $737 (5%) $896 (4%) $737 (9%)
Total treatment costs (all cycles) $3561 $13 841 $21 998 $7832
Terminal carea $12 326 $12 066 $12 070 $12 072
Total costs $27 132 $37 152 $45 313 $31 149
aTerminal care costs attributable to lung cancer can vary due to differential lengths of survival and competing risks from other diseases.
Table 2 Cost-effectiveness of various paclitaxel/cisplatin regimens compared to standard etoposide/cisplatin
Regimen Total cost Incremental cost Life-years gained Cost/life-year gained
Etoposide/cisplatin $27 132 – – –
Paclitaxel/cisplatin (24-h infusion) $37 152 $10 020 0.1312 $76 370
Paclitaxel/cisplatin/G-CSF (24-h infusion) $45 313 $18 181 0.1312 $138 578
Outpatient paclitaxel/cisplatin (3-h infusion) $31 149 $4017 0.1312 $30 619
Numbers may not add due to rounding.
Table 3 Selected sensitivity analyses of paclitaxel/cisplatin compared to
standard etoposide/cisplatin, with paclitaxel given by a 3-h outpatient infusion
Manipulation Cost per life-year gained
¯ survival by 25% $40 927
¯ survival by 50% $71 321
Stage IV patients only $44 756
Pre-generic paclitaxel costs $49 028
Compared to best supportive care $4539
Compared to best supportive care (stage IV only) $5114paclitaxel-containing arms. As a result, calculation of costs per
quality-adjusted life-year would not be expected to be significantly
different from the costs per life-year gained in our analyses. If
anything, improved quality of life would make paclitaxel/cisplatin
more cost-effective.
Lung cancer is not an overly expensive disease to treat.
However, by virtue of its high incidence it has a significant impact
on total health care expenditures. Despite being cost-effective,
treating all stage IV NSCLC patients in Canada with paclitaxel and
cisplatin as outpatients would cost $155 million, an additional
$15 million per annum compared to BSC. However, this is an
overestimate because oncologists in Canada are still very con-
servative towards the treatment of advanced lung cancer, and
would not offer treatment to all of their patients (Raby et al, 1995).
In addition, many patients are not candidates for systemic therapy
because of age, performance status, or co-morbid conditions.
Consequently, the actual impact on health budgets of bringing
paclitaxel/cisplatin into routine use is likely to be more modest. As
advances in cancer research make more treatments available,
society is increasingly asking practitioners to assess the costs and
the benefits of the treatments provided. Given these considera-
tions, outpatient paclitaxel/cisplatin chemotherapy can be consid-
ered both an effective and a cost-effective treatment for advanced
NSCLC that is competitive with many other commonly accepted
health care practices (Detsky and Naglie, 1990).
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